X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the research agreement, Cytocom will provide research funding to these 4 laboratories for projects of mutual interest or for research projects commissioned by Cytocom that explore immune modulation and the action of therapeutics on target toll-like receptors.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Recipient: La Jolla Institute
Deal Size: $1.4 million Upfront Cash: Undisclosed
Deal Type: Agreement August 12, 2021
Details:
Combined public entity to develop and commercialize next-generation immune therapies like CYTO-200, that address unmet needs in oncology, infectious disease, inflammation and auto-immune-mediated conditions.
Lead Product(s): CYTO-200
Therapeutic Area: Gastroenterology Product Name: CYTO-200
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cleveland Clinic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger February 17, 2021
Details:
Cytocom has submitted an Investigational New Drug (IND) application with updated protocols to the FDA to begin a Phase 2 clinical trial, to evaluate the safety and efficacy of CYTO-205 to slow or halt the progression of the SARS-CoV-2, the virus that causes COVID-19.
Lead Product(s): Naltrexone
Therapeutic Area: Infections and Infectious Diseases Product Name: CYTO-205
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2021
Details:
Merger to create a single public company focused on the development and commercialization of immunotherapies for oncology, infectious disease, inflammation and auto-immune mediated conditions. Portfolio includes investigational drug, CYTO-201, for COVID-19 infection.
Lead Product(s): Noroxymorphone analogs
Therapeutic Area: Gastroenterology Product Name: CYTO-201
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cleveland BioLabs
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger October 20, 2020
Details:
Based on the FDA's feedback, Cytocom plans to revise the protocol of Company's planned Phase 2 clinical trial of CYTO-201 for the treatment of SARS-CoV-2 and quickly initiate enrollment.
Lead Product(s): CYTO-201
Therapeutic Area: Infections and Infectious Diseases Product Name: CYTO-201
Highest Development Status: Phase IIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
